Provectus Biopharmaceuticals, Inc.

What they do

The company develops drug candidates and non-clinical formulations made from its proprietary, patented, pharmaceutical-grade RBS, delivered by different routes of administration for different diseases. Its pipeline includes clinical programs in oncology (intratumoral PV-10), dermatology (topical PH-10), and ophthalmology (topical PV-305), plus proof-of-concept and early discovery work in oral oncology, hematology, wound healing, and other areas. The company states it is the first entity to advance RBS into clinical trials for disease treatment and the only one to date to make pharmaceutical-grade RBS API at nearly 100% purity.

Revenue drivers

• No commercial product revenue — Provectus has no prescription drug products approved for commercial sale; annual revenue was $336,108 in 2025, down from $617,140 in 2024 and $557,710 in 2023, and the company has never generated substantial revenues.
• Clinical-stage drug candidates (no product sales) — PV-10 (intratumoral oncology), PH-10 (topical dermatology), and PV-305 (topical ophthalmology) are in clinical or non-clinical study and do not generate product revenue.
• Proof-of-concept and discovery programs — Oral PV-10 formulations, wound healing, vaccine adjuvants, infectious diseases, tissue regeneration, and in silico modeling are research-stage and produce no revenue.

Recent performance

Annual revenue was $336,108 in 2025, down from $617,140 in 2024 and $557,710 in 2023. Recent quarterly revenue has been uneven: $109,745 in Q3 2024, $14,332 in Q4 2024, $278,628 in Q1 2025, and $57,480 in Q2 2025. Net income was positive on a GAAP basis in recent years ($3.1M in 2023, $4.8M in 2024, $5.5M in 2025), but operating cash flow remained negative at approximately $3.3M in both 2024 and 2025. As of June 30, 2026, total assets were $1.5M, total liabilities were $7.8M, shareholder equity was negative $6.3M, and cash and equivalents were $1.2M. Diluted EPS has been $(0.01) in each year from 2021 through 2025.

Strategy

Management says it is selectively continuing and planning new monotherapy and/or combination therapy intratumoral PV-10 clinical trials for solid tumor cancers, aiming for drug approval pathways or co-development relationships. It is developing a systemically administered RBS formulation with goals to file an IND, take a candidate into early-stage clinical trials, and/or pursue co-development or out-licensing. For other disease areas and routes of administration, it is developing different RBS formulations to show non-clinical activity and lack of toxicity, with similar IND and partnering goals. The company is also funding academic research collaborations to characterize the RBS molecule and is doing analytical comparisons of non-pharmaceutical-grade rose bengal against its pharmaceutical-grade RBS. It launched VisiRose, Inc., a clinical-stage start-up with the University of Miami, to commercialize ocular research using PV-305.

Risks

• No approved products and no substantial revenue — Provectus has no prescription drug products approved for commercial sale, has never generated substantial revenues, and may never achieve profitability.
• Accumulated losses — As of December 31, 2025, the company had incurred net losses of approximately $263 million in the aggregate since inception in January 2002.
• Need for additional capital — The company states it needs additional capital in 2026 and beyond to continue developing and seeking to commercialize its drug candidates, and its ability to obtain necessary funding is uncertain.
• Negative operating cash flow — Operating cash flow was negative $3.3M in both 2024 and 2025, and the company expects negative operating cash flow for the foreseeable future.

Outlook

Management says it expects to continue incurring significant operating expenditures and anticipates that operating and capital expenses may increase substantially as it develops candidates and seeks regulatory approval. It expects negative operating cash flow for the foreseeable future and states it needs additional capital in 2026 and beyond, with no assurance that funding will be available. The company intends to continue ongoing and planned PV-10 clinical trials and to advance systemic RBS and other formulation work toward IND filings and potential partnerships.